[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-dissection-type-a\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-dissection-type-a":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,70,97,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100634226","triage-and-recognition-of-acute-aortic-dissection-in-chest-pain-by-electrocardiogram-artificial-intelligence-100634226",false,"NCT07536932","Triage and Recognition of Acute Aortic Dissection in Chest Pain by Electrocardiogram-Artificial Intelligence","A Multicenter Prospective Study to Develop and Validate an Artificial Intelligence-Based Electrocardiogram Model for the Diagnosis of Acute Type A Aortic Dissection in Patients Presenting With Chest Pain","TRACE","Inclusion Criteria:\n\n* Male or female emergency department patients aged 18-80 years;\n* Clear presentation of chest pain or related chest\u002Fback pain;\n* Completion of standard 12-lead electrocardiography (ECG) within 24 hours after onset of chest pain;\n* ECG signal quality meeting the following criteria: QRS amplitude ≥ 0.1 mV and noise proportion \\\u003C 20%;\n* Availability of subsequent diagnostic workup confirming whether the patient had acute type A aortic dissection (TAAD) or another definitive diagnosis.\n\nExclusion Criteria:\n\n* Poor-quality ECG recordings, defined as missing leads in ≥ 3 leads or severe baseline instability;\n* Indeterminate final diagnosis;\n* History of prior surgery involving the aortic valve, aortic root, or ascending aorta.","ALL","18 Years","80 Years",{"count":21,"type":22},10000,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this prospective multicenter observational study is to learn whether an artificial intelligence model based on electrocardiograms (ECGs) can help diagnose acute type A aortic dissection (TAAD) in adults who come to the emergency department with chest pain or related symptoms. The main question it aims to answer is:\n\nCan the AI-ECG model accurately distinguish TAAD from other causes of chest pain in a real-world emergency setting? Researchers will compare the AI model's ECG-based predictions with the final diagnosis confirmed by computed tomographic angiography (CTA), which is the reference standard. Participants will undergo routine emergency ECG testing and subsequent diagnostic evaluation as part of standard care. Clinical and ECG data will be collected from five tertiary hospitals, and the model's diagnostic performance will be assessed across centers.",[27,28],"Aortic Dissection Type A","Chest Pain","NOT_YET_RECRUITING","2026-04-11",{"date":32,"type":33},"2026-04-17","ACTUAL",{"date":35,"type":22},"2026-04",{"date":37,"type":22},"2026-12",{"name":39,"class":40},"Shanghai Zhongshan Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100568065","total-arch-replacement-with-frozen-elephant-trunk-versus-hemiarch-replacement-in-the-management-of-acute-type-a-aortic-dissection-100568065","NCT06676371","Total Arch Replacement With Frozen Elephant Trunk Versus Hemiarch Replacement in the Management of Acute Type A Aortic Dissection","Randomized Control Trial of Total Arch Replacement With Frozen Elephant Trunk Versus Conventional Hemiarch Replacement in Patients With Acute Type A Aortic Dissection (TARFET-TAAD)","TARFET-TAAD","Inclusion Criteria:\n\n1. Patient 's age is between 18 and 80 years.\n2. Patient is willing and able to give informed consent.\n3. Patient has acute type A aortic dissection with entry tear beyond ascending aorta.\n4. Patient not in coma\u002Firreversible end organ failure\u002Fcardiac massage for resuscitation\n\nExclusion Criteria:\n\n1. There is no identifiable entry tear in the aorta\n2. The ascending entry tear extends into aortic arch\n3. Patient has entry tear only in ascending aorta\n4. Patient with Type B aortic dissection\n5. Patient has co-morbidity (i.e. active malignancy (progressive, stable or partial remission)) causing expected survival to be less than 2 years.\n6. Patient has any other medical, social, or psychological problems, that in the opinion of the investigator, preclude the patient from participating in this study.",{"count":50,"type":22},150,"INTERVENTIONAL",[53],"NA","Acute Type A aortic dissection (ATAAD) and its complications are life-threatening conditions that cause more than 1400 hospital admissions and 300 deaths every year in Hong Kong and cause 172,927 deaths globally in 2019. There is an increasing trend in recent years.\n\nGiven the hyperacute presentation and complexity of the clinical manifestation with various mal-perfusion syndromes, the mortality of ATAAD remained high in all international reported registries and published series.\n\nConventional Hemiarch (HAR) replacement has been the gold standard procedure for ATAAD in most of cardiac surgical centers around the world because of the relative simplicity of the procedure. However, around 50-70% of patients were reported to develop distal anastomosis new entry after hemiarch procedure and for those with entry tear over aortic arch and distal mal-perfusion, hemiarch alone might not be able to solve the downstream problem. On the other hand, total arch replacement and frozen elephant trunk procedure (TARFET) is more complex, technically demanding procedure that could potentially cover\u002Fresect the arch entry tear and exclude tear over proximal descending thoracic aorta and, hence, solve the distal mal-perfusion syndrome. To date, there is no randomized control trial to answer whether HAR or TARFET procedure is superior in patients with ATAAD and entry tear is over the aortic arch or proximal descending thoracic aorta.\n\nWe plan to conduct a multi-center trial to recruit consecutive patients with ATAAD with entry tear beyond ascending aorta and randomized them, after informed consent, into either the conventional hemiarch replacement group (HAR) or total arch replacement and frozen elephant trunk (TARFET). The participating centers will collect pre- operative, intra-operative and post-operative clinical parameters for two groups of patients via REDCap system. Written informed consent, specifically allowing the use of clinical records for this randomized study, will be obtained from every patient prior to data collection. The primary outcome is the 30-day mortality of the ATAAD patients with surgically treated by HAR versus TARFET approach. The secondary outcomes are the major adverse cardiovascular and cerebral events, post-op renal replacement therapy, re-exploration for bleeding and re-intervention within 30-days.\n\nThis study will be the world's first multi-center randomized control trial in ATAAD to compare the 30-day mortality of patients treated with HAR and TARFET. It could be a guideline-changing study for the treatment of ATAAD and its impact on the surgical approach to patients suffering from ATAAD.",[27],[57,58,59],"Total Arch Replacement and Frozen Elephant Trunk (TARFET)","Conventional Hemiarch (HAR) replacement","Acute Type A aortic dissection (ATAAD)","2026-03-16",{"date":62,"type":33},"2026-03-18",{"date":64,"type":22},"2026-10",{"date":66,"type":22},"2029-10",{"name":68,"class":40},"Chinese University of Hong Kong",3,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":51,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":69},"100622460","remote-ischemic-preconditioning-for-aute-type-a-aortic-dissection-surgery-100622460","NCT07383909","Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery","Evaluation of the Organ-Protective Effects of Remote Ischemic Preconditioning in Patients Undergoing Surgery for Acute Type A Aortic Dissection: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥18 years, with no restriction on sex;\n2. Diagnosis of acute Type A aortic dissection requiring emergency surgery (symptom onset \\\u003C14 days);\n3. Ability to understand the study objectives, voluntary provision of written informed consent by the patient or a legally authorized representative, and willingness to comply with follow-up.\n\nExclusion Criteria:\n\n1. Traumatic or iatrogenic aortic dissection;\n2. Previous open cardiac or thoracic aortic surgery;\n3. Severe preoperative dysfunction of vital organs, such as persistent deep coma, abdominal compartment syndrome, or circulatory failure;\n4. Severe comorbidities, including myocardial infarction within the past 7 days, stroke within the past 2 months; end-stage renal disease (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²); end-stage liver disease (total bilirubin \\>342 μmol\u002FL or INR \\>2.0);\n5. Evidence of ischemia in the limb planned for intervention, such as decreased skin temperature, pain, pallor, with or without sensory disturbance, paralysis, or diminished\u002Fabsent pulses; or severe deformity or prior arteriovenous surgery at the intervention site;\n6. Peripheral arterial disease involving the limbs, Raynaud phenomenon, active phlebitis, or a history of deep vein thrombosis of the lower extremities;\n7. Current use of sulfonylurea oral hypoglycemic agents or nicorandil;\n8. Life expectancy \\\u003C1 year (e.g., advanced malignancy);\n9. Participation in another clinical trial without having reached its primary endpoint;\n10. Pregnancy or lactation; immunodeficiency (e.g., HIV positivity, history of organ transplantation); known bleeding disorders, coagulation abnormalities, or sickle cell anemia; active or uncontrolled infection;\n11. Other severe physical or psychiatric disorders, or laboratory abnormalities, which in the investigator's judgment may increase risk or interfere with study outcomes, rendering the patient unsuitable for enrollment.",{"count":78,"type":22},1296,[53],"The goal of this clinical trial is to learn if a technique called remote ischemic preconditioning (RIPC) helps protect organs during emergency surgery for acute type A aortic dissection (ATAAD). The main questions it aims to answer are:\n\nDoes RIPC reduce the risk of major complications after surgery, such as heart, brain, or kidney problems?\n\nIs RIPC safe to use during emergency ATAAD surgery?\n\nResearchers will compare the RIPC group to a control group (who will receive a placebo) to see if RIPC can reduce complications after surgery.\n\nParticipants will:\n\nReceive either RIPC or a sham intervention during their surgery.\n\nBe monitored for up to 30 days after surgery for complications.\n\nHave follow-up visits at 3 months, 1 year, and then yearly for up to 5 years to track their recovery.",[27],[83,84,85,86],"Remote Ischaemic Conditioning","ischemia reperfusion injury","emergency surgery","major adverse outcomes","RECRUITING","2026-01-26",{"date":90,"type":33},"2026-02-03",{"date":92,"type":33},"2026-01-05",{"date":94,"type":22},"2032-12-31",{"name":96,"class":40},"Fujian Medical University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":51,"phases":107,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100593378","phase-2-use-of-prp-in-open-surgery-for-type-a-aortic-dissection-100593378","NCT07005661","Use of PRP in Open Surgery for Type A Aortic Dissection","Multicenter, Prospective, Randomized Controlled Trial of Autologous Platelet Rich Plasma (PRP) Use in Open Surgery for Type A Aortic Dissection","Inclusion Criteria:\n\n1. Undergoing open surgery for type A aortic dissection (TAAD);\n2. Body weight between 60-100 kg; hemoglobin (Hb) \\> 120 g\u002FL; platelet count (PLT) ≥ 120 × 10⁹\u002FL;\n3. Able to understand the purpose of the study, voluntarily participate, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Requires mechanical ventilation before surgery;\n2. Age under 18 or over 70 years;\n3. Use of anticoagulant or antiplatelet drugs within 7 days before surgery;\n4. Cardiogenic shock, cardiac arrest, severe hypotension (requiring two or more vasopressors), or mechanical circulatory support within 24 hours before surgery;\n5. Renal failure requiring dialysis;\n6. Severe coagulopathy or active bleeding tendency;\n7. Known history of heparin-induced thrombocytopenia (HIT);\n8. Severe psychiatric illness or other conditions affecting study reliability;\n9. Any condition deemed unsuitable by the investigator.","70 Years",{"count":106,"type":22},250,[108,109],"PHASE2","PHASE3","The goal of this clinical trial is to determine if autologous platelet rich plasma (PRP) can reduce the need for blood transfusions in patients undergoing open surgery for Type A aortic dissection. It will also evaluate the potential organ-protective effects of autologous PRP. The main questions it aims to answer are:\n\n1. Does PRP reduce the amount of allogeneic red blood cell transfusions for participants?\n2. Does PRP administration provide protective effects on organs (heart, liver, lungs, kidneys, brain) in participants?\n\nResearchers will compare the administration of autologous PRP with no PRP infusion to assess whether PRP can reduce blood transfusions and provide organ-protective effects in patients undergoing open surgery for Type A aortic dissection.\n\nParticipants will:\n\n1. Receive autologous PRP infusion during surgery\n2. Undergo multiple checkups and tests before and after surgery\n3. Be recorded for allogeneic red blood cell usage within 24 hours perioperatively and all allogeneic blood products usage during the entire hospitalization\n4. Be assessed for organ function (heart, liver, lungs, kidneys, brain) and symptom-related outcomes through clinical evaluations",[27,112,113,114],"Transfusions","Platelet Rich Plasma (PRP)","Organ Protection",[116,117,118],"aortic dissection","transfusions","platelet rich plasma","2025-06-03",{"date":121,"type":33},"2025-06-05",{"date":123,"type":22},"2025-06-30",{"date":125,"type":22},"2028-10-31",{"name":127,"class":40},"Beijing Anzhen Hospital",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":51,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100465346","protective-effect-of-thymosin-1-against-negative-immune-dysregulation-and-organ-dysfunction-after-acute-aortic-dissection-surgery-panda-ii-100465346","NCT05339529","Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)","PANDA","Inclusion Criteria:\n\n* The patients are conformed to 2010 ACC\u002FAHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;\n* Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled.\n* The patients' age between 18 \\~90 years old.\n* Agree to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n* Patients allergic to Thymosin α1;\n* Lactating women and pregnant women;\n* Patients with mental diseases, drug and alcohol dependence;\n* Refuse to participate in this study and refuse to sign the informed consent.","90 Years",{"count":137,"type":22},330,[53],"Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.",[141,142],"Acute Aortic Syndrome","Aortic Dissection Type a","2024-12-09",{"date":145,"type":33},"2024-12-12",{"date":147,"type":33},"2022-07-01",{"date":149,"type":22},"2025-12-31",{"name":151,"class":40},"Nanjing Medical University",15]